DICE Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
October 17, 2022 16:05 ET
|
DICE Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline...
DICE Announces Pricing of Upsized Public Offering of Common Stock
October 12, 2022 20:10 ET
|
DICE Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline...
DICE Announces Proposed Public Offering of Common Stock
October 11, 2022 16:01 ET
|
DICE Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline...
DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis
October 11, 2022 07:00 ET
|
DICE Therapeutics, Inc.
Clinical proof-of-concept in psoriasis patients achieved with a mean percentage reduction in PASI from baseline at 4 weeks of 43.7% in the high dose group compared to 13.3% in the placebo group, with...
DICE Therapeutics Reports Second Quarter 2022 Financial Results and Recent Highlights
August 11, 2022 16:10 ET
|
DICE Therapeutics, Inc.
Completed enrollment in Phase 1 clinical trial of lead oral IL-17 antagonist DC-806; topline proof-of-concept data in healthy volunteers and psoriasis patients expected in 2H 2022 SOUTH SAN...
DICE Therapeutics Announces Completion of Enrollment in Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for the Treatment of Psoriasis
July 21, 2022 16:05 ET
|
DICE Therapeutics, Inc.
Topline proof-of-concept data in healthy volunteers and psoriasis patients expected in 2H 2022 SOUTH SAN FRANCISCO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE),...
DICE Therapeutics to Present at the 2022 Jefferies Healthcare Conference
June 01, 2022 16:05 ET
|
DICE Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline...
DICE Therapeutics Reports First Quarter 2022 Financial Results and Recent Highlights
May 12, 2022 16:05 ET
|
DICE Therapeutics, Inc.
Topline proof-of-concept data from Phase 1 clinical trial of oral IL-17 antagonist DC-806 in healthy volunteers and psoriasis patients expected in mid-2022Current cash provides runway through mid-2024...
DICE Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
May 03, 2022 08:00 ET
|
DICE Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline...
DICE Therapeutics Expands Management Team and Board of Directors
March 28, 2022 16:05 ET
|
DICE Therapeutics, Inc.
Mary Riley, J.D., appointed as general counselLisa Bowers, MHSA, and Mittie Doyle, M.D., FACR, join board of directors SOUTH SAN FRANCISCO, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- DICE...